Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -0.20% | 12.92% | 29.43% | 50.74% | -98.55% |
| Total Depreciation and Amortization | 428.62% | 277.84% | 140.31% | 19.15% | -10.05% |
| Total Amortization of Deferred Charges | -86.36% | -36.20% | 81.57% | 641.26% | 368.16% |
| Total Other Non-Cash Items | -84.97% | -83.10% | -87.09% | -95.90% | 193.30% |
| Change in Net Operating Assets | 226.94% | -73.98% | -460.01% | 1.98% | -514.44% |
| Cash from Operations | -69.37% | -103.54% | -80.89% | -39.59% | -51.77% |
| Capital Expenditure | -3,293.75% | -11,462.59% | -12,630.95% | -1,745.27% | 49.12% |
| Sale of Property, Plant, and Equipment | -73.57% | -81.38% | -75.45% | -77.99% | -79.30% |
| Cash Acquisitions | -- | -- | -- | -100.00% | -80.02% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,295.95% | -742.93% | -103.72% | -102.80% | -79.91% |
| Total Debt Issued | -- | -- | -- | -100.00% | 630.46% |
| Total Debt Repaid | -- | -- | -- | 97.43% | 90.00% |
| Issuance of Common Stock | -93.41% | -93.41% | 667.44% | 632.16% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2,266.73% | -2,273.44% | -2,273.44% | -4,318.33% | -- |
| Cash from Financing | -99.98% | -102.05% | 408.19% | 406.26% | 44,363.54% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.83% | -151.26% | 539.10% | 351.61% | 3,577.66% |